Integer Holdings Corporation's stock surged 6.96% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results, which exceeded analyst expectations across key metrics.

The medical device maker reported Q4 sales of $472 million, beating the consensus estimate of $462.7 million. Adjusted earnings per share for the quarter came in at $1.76, surpassing the estimated $1.70. The strong performance was primarily driven by an 11% sales growth in the Cardio & Vascular segment, fueled by acquisitions and robust demand in Neurovascular.

Furthermore, the company provided optimistic guidance for 2026, expecting sales in the range of $1.83 billion to $1.88 billion, compared to the FactSet estimate of $1.84 billion. Adjusted EPS is projected to be between $6.29 and $6.78, versus the consensus estimate of $6.30. Integer also announced its intention to commence an accelerated share repurchase program of $50 million and expects to return to 200 basis points above-market organic sales growth in 2027.